Committee Composition

  Audit Nominating and Governance Compensation Strategic
John T. Henderson, M.D. Chairman of the Board Independent Director   Member of Nominating and Governance Committee Member of Compensation Committee Committee Chair for Strategic Committee
Lawrence C. Best Independent Director Member of Audit Committee     Member of Strategic Committee
Heiner Dreismann, Ph.D. Independent Director     Committee Chair for Compensation Committee Member of Strategic Committee
Heiner Dreismann Director

Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.

Walter Gilbert, Ph.D. Independent Director     Member of Compensation Committee  
Dennis Langer, M.D, J.D. Independent Director Member of Audit Committee Committee Chair for Nominating and Governance Committee    
S. Louise Phanstiel Independent Director Committee Chair for Audit Committee Member of Nominating and Governance Committee    
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director

Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Stock Quote (NASDAQ:MYGN)

- 0.80
Previous Close:
Day High:
Day Low:
52 Week High:
52 Week Low:
4:00 PM ET on Jul 22, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065